title: Too much disclosure of product risks? CBC television, SOGC, and Diane-35.
authors.affiliation: Centre for Health Services and Policy Research, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Barbara
authors.initials: B
authors.lastname: Mintzes
authors.forename: Joel
authors.initials: J
authors.lastname: Lexchin
authors.forename: Abby
authors.initials: A
authors.lastname: Lippman
authors.forename: Anne Rochon
authors.initials: AR
authors.lastname: Ford
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy; D000329:Advertising; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D002170:Canada; D017373:Cyproterone Acetate / Q000009:adverse effects* / Q000627:therapeutic use; D030881:Disclosure; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016017:Odds Ratio; D012307:Risk Factors; D014481:United States; D020246:Venous Thrombosis / Q000139:chemically induced*
chemical_list: D000726:Androgen Antagonists; D004338:Drug Combinations; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination